The US Centers for Medicare & Medicaid Services granted reimbursement for Illumina’s TruSight Oncology Comprehensive assay at $2,989.55 per test, effective Jan. 1, 2026. CMS specified payment under PLA code 0543U for the FDA‑approved comprehensive genomic profiling (CGP) test that interrogates >500 genes in solid tumor tissue. Illumina called the decision a removal of barriers to broader adoption of CGP; the company noted the assay’s companion diagnostic approvals for NTRK and RET fusions. Illumina’s senior director of market access commented the ruling supports precision oncology uptake and care decisions. The CMS move may shift hospital and community oncology testing patterns toward centralized CGP platforms that inform targeted therapy selection and trial enrollment.